This year we are celebrating 25 years of smarter studies, global impact, and better health. '25 at 25' is a series of articles highlighting 25 of our major achievements.

Latest News

New podcast episode: Who benefits most from a treatment?

In the latest episode of the Trial Talk podcast, Peter Godolphin and David Fisher discuss the new ‘within-trial framework for subgroup analysis’, as well as how other meta-analysis researchers can use it.

12 Mar

Excess inflammation linked to AIDS and other serious complications in adults on treatment for HIV

A sub-study from the START trial found that higher levels of inflammation averaged over the trial follow-up period were associated with a subsequent higher risk of AIDS, serious non-AIDS complications, or death during 6 …

07 Mar

ODYSSEY confirms dolutegravir-based treatment is best for children living with HIV

New extended follow-up results from the global ODYSSEY clinical trial confirm that dolutegravir-based regimens are superior to other antiretroviral treatments for children living with HIV.

07 Mar

‘25 at 25’: Optimising treatments for people with cancer

As part of our 25th anniversary celebrations, we explore our trials that aim to improve quality of life by optimising treatments for people with cancer.

06 Mar

More News

Research Themes

Cancer cells

Cancer

Innovative clinical trial design and meta-analysis extending beyond the boundaries of single cancer types

 

Infections

Major international clinical trials answering questions of global public health significance

Neurodegenerative diseases

New generation of innovative multi-arm multi-stage trials to identify and test new therapeutic treatments in neurodegenerative diseases (NDD)

Methodology

Development of methods with direct impact on the design, conduct and analysis of studies

 

 

Other Research & Policy

This section will capture projects outside the current QQR themes

Latest Podcasts